Start of the SelectImmune Pharma Phase II trial of targeted immunotherapy in recurrent acute cystitis
SelectImmune Pharma is proud to report that the Phase II trial of the IL-1 receptor antagonist (IL-1RA) in patients with recurrent acute cystitis has started. The clinical trial is led by Professor Wagenlehner, an international key opinion leader in the field of urinary tract infection therapy and antibiotic resistance at the center for such studies in Giessen, Germany, in collaboration with scientists at Lund University and SelectImmune.The formal clinical trial preparations to obtain permission for the study from the German regulatory authorities and ethical committee have been completed